TAK
Takeda Pharmaceutical Company Limited
Drug Manufacturers - Specialty & Generic
Market Cap$52.57B
5Y Perf.-14.7%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
TAK vs SNY
Revenue, margins, valuation, and 5-year total return — side by side.
SNY
Sanofi
Drug Manufacturers - General
Market Cap$104.28B
5Y Perf.-12.1%
TAK vs SNY — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TAK | SNY |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - General |
| Market Cap | $52.57B | $104.28B |
| Revenue (TTM) | $4.49T | $46.72B |
| Net Income (TTM) | $114.75B | $7.81B |
| Gross Margin | 62.1% | 72.3% |
| Operating Margin | 8.3% | 13.6% |
| Forward P/E | 0.2x | 10.3x |
| Total Debt | $4.52T | $21.79B |
| Cash & Equiv. | $385.11B | $7.66B |
TAK vs SNY — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TAK
SNY
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Takeda Pharmaceutic… (TAK) | 100 | 85.3 | -14.7% |
| Sanofi (SNY) | 100 | 87.9 | -12.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TAK vs SNY
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TAK leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Sanofi is the stronger pick specifically for profitability and margin quality and dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
TAK
Takeda Pharmaceutical Company Limited
The Income Pick
TAK carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 2 yrs, beta 0.33, yield 3.6%
- Rev growth 7.5%, EPS growth -26.2%, 3Y rev CAGR 8.7%
- Lower volatility, beta 0.33, Low D/E 65.1%, current ratio 1.01x
Best for: income & stability and growth exposure
SNY
Sanofi
The Long-Run Compounder
SNY is the clearest fit if your priority is long-term compounding and defensive.
- 57.1% 10Y total return vs TAK's -1.4%
- Beta 0.51, yield 5.1%, current ratio 1.09x
- 16.7% margin vs TAK's 2.6%
Best for: long-term compounding and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TAK | 7.5% revenue growth vs SNY's 5.5% |
| Value | TAK | Lower P/E (0.2x vs 10.3x) |
| Quality / Margins | SNY | 16.7% margin vs TAK's 2.6% |
| Stability / Safety | TAK | Beta 0.33 vs SNY's 0.51 |
| Dividends | SNY | 5.1% yield, vs TAK's 3.6% |
| Momentum (1Y) | TAK | +14.6% vs SNY's -9.8% |
| Efficiency (ROA) | SNY | 6.1% ROA vs TAK's 0.7%, ROIC 5.5% vs 2.3% |
TAK vs SNY — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
TAK vs SNY — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTAKLAGGINGSNY
SNYSanofi
2leads
TAKTakeda Pharmaceutical…
3leads
6 Total Categories
CATEGORYLEADERvs SNYMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SNY4/6
Valuation MetricsMultiples, price ratios, and targets
TAK4/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SNY9/9
Total Returns1Y, 3Y, 5Y total returns with dividends
TAK5/6
Risk & VolatilityBeta, volatility, and downside exposure
TAK2/2
Analyst OutlookRatings, price targets, and dividends
Tied
—
Income & Cash Flow (Last 12 Months)
SNY leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TAK is the larger business by revenue, generating $4.49T annually — 96.0x SNY's $46.7B. SNY is the more profitable business, keeping 16.7% of every revenue dollar as net income compared to TAK's 2.6%. On growth, SNY holds the edge at +59.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | TAKTakeda Pharmaceut… | SNYSanofi |
|---|---|---|
| RevenueTrailing 12 months | $4.49T | $46.7B |
| EBITDAEarnings before interest/tax | $1.14T | $9.6B |
| Net IncomeAfter-tax profit | $114.8B | $7.8B |
| Free Cash FlowCash after capex | $956.6B | $8.3B |
| Gross MarginGross profit ÷ Revenue | +62.1% | +72.3% |
| Operating MarginEBIT ÷ Revenue | +8.3% | +13.6% |
| Net MarginNet income ÷ Revenue | +2.6% | +16.7% |
| FCF MarginFCF ÷ Revenue | +21.3% | +17.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +6.0% | +59.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +3.4% | -5.2% |
SNY leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
TAK leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 18.1x trailing earnings, SNY trades at a 77% valuation discount to TAK's 77.4x P/E. On an enterprise value basis, SNY's 10.8x EV/EBITDA is more attractive than TAK's 11.2x.
| Metric | TAKTakeda Pharmaceut… | SNYSanofi |
|---|---|---|
| Market CapShares × price | $52.6B | $104.3B |
| Enterprise ValueMkt cap + debt − cash | $79.0B | $120.9B |
| Trailing P/EPrice ÷ TTM EPS | 77.38x | 18.10x |
| Forward P/EPrice ÷ next-FY EPS est. | 0.23x | 10.26x |
| PEG RatioP/E ÷ EPS growth rate | 4.09x | — |
| EV / EBITDAEnterprise value multiple | 11.19x | 10.77x |
| Price / SalesMarket cap ÷ Revenue | 1.79x | 1.90x |
| Price / BookPrice ÷ Book value/share | 1.20x | 1.25x |
| Price / FCFMarket cap ÷ FCF | 9.60x | 9.98x |
TAK leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
SNY leads this category, winning 9 of 9 comparable metrics.
Profitability & Efficiency
SNY delivers a 10.8% return on equity — every $100 of shareholder capital generates $11 in annual profit, vs $2 for TAK. SNY carries lower financial leverage with a 0.30x debt-to-equity ratio, signaling a more conservative balance sheet compared to TAK's 0.65x. On the Piotroski fundamental quality scale (0–9), SNY scores 7/9 vs TAK's 5/9, reflecting strong financial health.
| Metric | TAKTakeda Pharmaceut… | SNYSanofi |
|---|---|---|
| ROE (TTM)Return on equity | +1.5% | +10.8% |
| ROA (TTM)Return on assets | +0.7% | +6.1% |
| ROICReturn on invested capital | +2.3% | +5.5% |
| ROCEReturn on capital employed | +2.8% | +6.3% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 7 |
| Debt / EquityFinancial leverage | 0.65x | 0.30x |
| Net DebtTotal debt minus cash | $4.13T | $14.1B |
| Cash & Equiv.Liquid assets | $385.1B | $7.7B |
| Total DebtShort + long-term debt | $4.52T | $21.8B |
| Interest CoverageEBIT ÷ Interest expense | 1.97x | 17.51x |
SNY leads this category, winning 9 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
TAK leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TAK five years ago would be worth $11,761 today (with dividends reinvested), compared to $10,252 for SNY. Over the past 12 months, TAK leads with a +14.6% total return vs SNY's -9.8%. The 3-year compound annual growth rate (CAGR) favors TAK at 2.7% vs SNY's -2.4% — a key indicator of consistent wealth creation.
| Metric | TAKTakeda Pharmaceut… | SNYSanofi |
|---|---|---|
| YTD ReturnYear-to-date | +8.4% | -6.8% |
| 1-Year ReturnPast 12 months | +14.6% | -9.8% |
| 3-Year ReturnCumulative with dividends | +8.5% | -7.0% |
| 5-Year ReturnCumulative with dividends | +17.6% | +2.5% |
| 10-Year ReturnCumulative with dividends | -1.4% | +57.1% |
| CAGR (3Y)Annualised 3-year return | +2.7% | -2.4% |
TAK leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
TAK leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
TAK is the less volatile stock with a 0.33 beta — it tends to amplify market swings less than SNY's 0.51 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TAK currently trades 88.1% from its 52-week high vs SNY's 80.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TAKTakeda Pharmaceut… | SNYSanofi |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.33x | 0.51x |
| 52-Week HighHighest price in past year | $18.89 | $53.36 |
| 52-Week LowLowest price in past year | $12.99 | $43.09 |
| % of 52W HighCurrent price vs 52-week peak | +88.1% | +80.9% |
| RSI (14)Momentum oscillator 0–100 | 39.5 | 34.1 |
| Avg Volume (50D)Average daily shares traded | 2.8M | 3.2M |
TAK leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Evenly matched — TAK and SNY each lead in 1 of 2 comparable metrics.
Analyst Outlook
Wall Street rates TAK as "Buy" and SNY as "Buy". For income investors, SNY offers the higher dividend yield at 5.11% vs TAK's 3.62%.
| Metric | TAKTakeda Pharmaceut… | SNYSanofi |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $50.00 |
| # AnalystsCovering analysts | 6 | 27 |
| Dividend YieldAnnual dividend ÷ price | +3.6% | +5.1% |
| Dividend StreakConsecutive years of raises | 2 | 0 |
| Dividend / ShareAnnual DPS | $94.22 | $1.88 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.6% | +5.4% |
Evenly matched — TAK and SNY each lead in 1 of 2 comparable metrics.
Key Takeaway
TAK leads in 3 of 6 categories (Valuation Metrics, Total Returns). SNY leads in 2 (Income & Cash Flow, Profitability & Efficiency). 1 tied.
Best OverallTakeda Pharmaceutical Compa… (TAK)Leads 3 of 6 categories
Loading custom metrics...
TAK vs SNY: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is TAK or SNY a better buy right now?
For growth investors, Takeda Pharmaceutical Company Limited (TAK) is the stronger pick with 7.
5% revenue growth year-over-year, versus 5. 5% for Sanofi (SNY). Sanofi (SNY) offers the better valuation at 18. 1x trailing P/E (10. 3x forward), making it the more compelling value choice. Analysts rate Takeda Pharmaceutical Company Limited (TAK) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — TAK or SNY?
On trailing P/E, Sanofi (SNY) is the cheapest at 18.
1x versus Takeda Pharmaceutical Company Limited at 77. 4x. On forward P/E, Takeda Pharmaceutical Company Limited is actually cheaper at 0. 2x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — TAK or SNY?
Over the past 5 years, Takeda Pharmaceutical Company Limited (TAK) delivered a total return of +17.
6%, compared to +2. 5% for Sanofi (SNY). Over 10 years, the gap is even starker: SNY returned +57. 1% versus TAK's -1. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — TAK or SNY?
By beta (market sensitivity over 5 years), Takeda Pharmaceutical Company Limited (TAK) is the lower-risk stock at 0.
33β versus Sanofi's 0. 51β — meaning SNY is approximately 58% more volatile than TAK relative to the S&P 500. On balance sheet safety, Sanofi (SNY) carries a lower debt/equity ratio of 30% versus 65% for Takeda Pharmaceutical Company Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — TAK or SNY?
By revenue growth (latest reported year), Takeda Pharmaceutical Company Limited (TAK) is pulling ahead at 7.
5% versus 5. 5% for Sanofi (SNY). On earnings-per-share growth, the picture is similar: Sanofi grew EPS -7. 3% year-over-year, compared to -26. 2% for Takeda Pharmaceutical Company Limited. Over a 3-year CAGR, TAK leads at 8. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — TAK or SNY?
Sanofi (SNY) is the more profitable company, earning 16.
7% net margin versus 2. 4% for Takeda Pharmaceutical Company Limited — meaning it keeps 16. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SNY leads at 13. 6% versus 7. 5% for TAK. At the gross margin level — before operating expenses — SNY leads at 72. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is TAK or SNY more undervalued right now?
On forward earnings alone, Takeda Pharmaceutical Company Limited (TAK) trades at 0.
2x forward P/E versus 10. 3x for Sanofi — 10. 0x cheaper on a one-year earnings basis.
08Which pays a better dividend — TAK or SNY?
All stocks in this comparison pay dividends.
Sanofi (SNY) offers the highest yield at 5. 1%, versus 3. 6% for Takeda Pharmaceutical Company Limited (TAK).
09Is TAK or SNY better for a retirement portfolio?
For long-horizon retirement investors, Takeda Pharmaceutical Company Limited (TAK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
33), 3. 6% yield). Both have compounded well over 10 years (TAK: -1. 4%, SNY: +57. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between TAK and SNY?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(TAK: 6.0% · SNY: 59.9%)Net Margin>
%
(TAK: 2.6% · SNY: 16.7%)P/E Ratio<
x
(TAK: 77.4x · SNY: 18.1x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.